Loading...
•
Mar 31, 2020
Amgen Q1 2020 Earnings Report
Amgen's financial performance was driven by increased unit demand, offset by lower net selling prices.
Key Takeaways
Amgen reported an 11% increase in total revenues to $6.2 billion for Q1 2020 compared to Q1 2019. GAAP EPS decreased by 3% to $3.07, while non-GAAP EPS increased by 17% to $4.17. The company generated $2.0 billion in free cash flow during the quarter and reaffirmed its 2020 total revenue guidance.
Total revenues increased by 11% to $6.2 billion due to higher unit demand.
GAAP EPS decreased by 3% to $3.07, influenced by Otezla acquisition costs.
Non-GAAP EPS increased by 17% to $4.17, driven by higher revenues and fewer shares outstanding.
The company generated $2.0 billion in free cash flow.
Amgen
Amgen
Amgen Revenue by Segment
Amgen Revenue by Geographic Location
Revenue by Segment
Repatha Revenue
CapyFin.comEVENITY Revenue
CapyFin.comProlia Revenue
CapyFin.comOtezla Revenue
CapyFin.comEnbrel Revenue
CapyFin.comKyprolis Revenue
CapyFin.comXGEVA Revenue
CapyFin.comVectibix Revenue
CapyFin.comNplate Revenue
CapyFin.comBLINCYTO Revenue
CapyFin.comAranesp Revenue
CapyFin.comParsabiv Revenue
CapyFin.comAMJEVITA / AMGEVITA Revenue
CapyFin.comMVASI Revenue
CapyFin.comNeulasta Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
Amgen reaffirmed its full-year 2020 guidance for total revenues and non-GAAP EPS.
Positive Outlook
- Total revenues are expected to be in the range of $25.0 billion to $25.6 billion.
- GAAP EPS is projected to be between $10.65 and $11.45.
- The GAAP tax rate is anticipated to be in the range of 10.5% to 11.5%.
- Non-GAAP EPS is expected to be in the range of $14.85 to $15.60.
- The non-GAAP tax rate is projected to be between 13.5% and 14.5%.
Revenue & Expenses
Visualization of income flow from segment revenue to net income